Future studies are needed to provide mechanistic insights—eg, whether plasma or urinary cGMP coupled with ANP levels could be an important surrogate for the prediction of response to ARNi therapy among patients with advanced HF. The gene discussed is NPPA; the disease is hydrops fetalis.